Non Small Cell Lung Cancer (NSCLC)

Stage IV / Metastatic - 2nd Line - Immunotherapy

Tumor-Infiltrating Lymphocytes (TIL)

VAR0241
Phase I/II Open-Label Study of PD-1 Knockout Tumor-Infiltrating Lymphocytes (IOV-4001) in Unresectable or Metastatic Melanoma or Stage III or IV Non-Small-Cell Lung Cancer
PI: Betof Warner Sponsor: Iovance Biotherapeutics, Inc.

VAR0251
Phase I Safety & Efficacy of LYL845 in Adults w/ Relapsed &/or Refractory Metastatic or Locally Advanced Melanoma & Selected Solid Tumor Malignancies
PI: Betof Warner Sponsor: Lyell Immunopharma Inc.

Progressed on Immunotherapy

Without Actionable Genomic Alterations

LUN0131
Phase IB Dose-Escalation & Expansion Study of the Safety & Efficacy of XL092 in Combo w/ Immuno-Oncology Agents in Unresectable Advanced or Metastatic Solid Tumors
PI: Neal Sponsor: Exelixis, Inc.